Table 4.
Comparison of outcomes between E-only MHT and unexposed participants
| Outcome | No. of participants (annualized %) | Unadjusted HR (95% CI) |
Adjusted HR (95% CI)* |
|
|---|---|---|---|---|
| E-only MHT (n=1,208) |
E-only unexposed (n=2,055) |
|||
| Follow-up time in months mean (range) | 111.6 (6.5–126.9) | 111.3 (0.75–126.9) | NA | NA |
| Acute MI | 9 (0.08) | 20 (0.10) | 0.76 (0.35–1.68) | 0.69 (0.31–1.52) |
| CHD Death | 2 (0.02) | 6 (0.03) | 0.57 (0.11–2.80) | 0.45 (0.09–2.30) |
| Breast cancer | 50 (0.43) | 59 (0.31) | 1.44 (0.99–2.10) | 1.39 (0.95–2.03) |
| Stroke | 81 (0.69) | 135 (0.71) | 1.02 (0.77–1.35) | 0.97 (0.73–1.28) |
| CABG/PTCA | 12 (0.10) | 16 (0.08) | 1.35 (0.63–2.89) | 1.11 (0.52–2.40) |
| PE | 3 (0.03) | 2 (0.01) | 2.53 (0.42–15.2) | 2.75 (0.45–16.8) |
| DVT | 16 (0.14) | 7 (0.04) | 3.89 (1.60–9.46) | 3.63 (1.48–8.89) |
| Colon cancer | 7 (0.06) | 12 (0.06) | 0.99 (0.39–2.51) | 0.99 (0.38–2.57) |
| Endometrial cancer | 10 (0.09) | 12 (0.06) | 1.41 (0.61–3.28) | 1.31 (0.56–3.09) |
| Any cancer | 277 (2.37) | 313 (1.65) | 1.59 (1.35–1.87) | 1.63 (1.39–1.93) |
| Vertebral and hip fractures | 41 (0.37) | 61 (0.32) | 1.14 (0.77–1.70) | 1.14 (0.75–1.70) |
| Any fracture | 91 (0.83) | 178 (0.97) | 0.86 (0.67–1.11) | 0.87 (0.67–1.12) |
| Death | 73 (0.62) | 134 (0.70) | 0.92 (0.69–1.23) | 0.89 (0.67–1.19) |
| Global Index | 225 (2.20) | 357 (2.0) | 1.09 (0.92–1.28) | 1.08 (0.92–1.29) |
*
Adjusted for age, statin use, aspirin use, hypercholesterolemia, diabetes medication use, hypertension